# A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

> **NCT07169175** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **SineuGene Therapeutics Co., Ltd.** · enrollment: 21 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** SNUG01

## Key facts

- **NCT ID:** NCT07169175
- **Lead sponsor:** SineuGene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169175, "A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07169175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*